Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

In oncology, we were delighted that Jemperli received an expanded approval by the FDA for all adult patients with primary advanced or recurrent endometrial cancer. And Blenrep is now filed with ...

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at Replays of the webcasts will be available for at least 30 days following the events. Anaptys is ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

U.S. drugmakers and biotechs have come to rely on Chinese partners. Now, some of them are looking for alternatives as ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

The WuXi companies make the raw materials for cancer drugs Imbruvica and Jemperli, among other drugs, according to supply-chain analytics firm Qyobo. Among listed U.S. biotechs and pharmaceutical ...

Jemperli added £130 million to GSK’s top line compared with £108 million in second-quarter 2024, driven by new patient starts ...